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Abstract 
Born global bio-enterprises are a unique “breed” of relatively small biotechnology 
enterprises operating in multiple countries. The companies are nimble and seemingly well-
prepared for challenges that ephemeral markets such as the internationalised biotechnology 
sector brings. The international marketing management challenges they encounter appear to 
stimulate their entrepreneurial marketing and commercialisation instincts. Surprisingly, there 
is a dearth of studies that examine their entrepreneurial predispositions. As such, this study 
is an attempt to explain their entrepreneurial tendencies by investigating the marketing and 
commercialisation strategies adopted by born global bio-enterprises in the UK’s 
biotechnology industry. The study assumes a multi-case approach examining five archetypical 
born global bio-enterprises currently active in the UK. It contributes to the international 
entrepreneurship and marketing management literature. Specifically, it provides international 
business managers with new knowledge about various marketing manoeuvres they can apply 
in international networks for their marketing mileage. In doing so, the study proposes a 
theoretical framework mapping out entrepreneurial marketing and commercialisation 
arrangements in internationalised biotechnology markets. Its findings are useful to various 
stakeholders including: policy makers, managers of technology-based companies and 
business management researchers.  
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1. Introduction 
The last two decades have recorded a marked rise, in numbers, of new bio-enterprises 
participating in international biotechnology markets. This has been made possible by the 
exponential growth in the number of approved products as a result of biotechnology 
processes, market capitalisation and revenues (Kermani and Bonacossa 2003). Although the 
sampled bio-enterprises are small in size they seem to be taking advantage of this 
development in biotechnology by forging business-like links in multiple countries enabling 
them to access strategic marketing capabilities (Johnson et al., 2008). These small but 
international-oriented companies, whose business model was seen as identical to that of a 
multinational enterprise in Simba (2013), were first reported in a study by Rennie (1993). 
Rennie termed these companies born globals.   
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In his study, Rennie (1993) also described these born globals as relatively small and young 
companies which began exporting, on average, two years following their inception and three 
quarters of their sales were generated from exports in their 3rd year of operation. Their 
smallness or newness in international markets were identified as barriers that somewhat 
confine their ability to carry out marketing and commercialisation activities (Aldrich and 
Auster, 1986; Baum et al., 2000). Hallback and Gabrielsson (2013) explained that this forced 
them to implement entrepreneurial marketing methods in targeted international markets. 
Based on this rationale, it would be especially interesting to explore the marketing and 
commercialisation arrangements of born global bio-enterprises in a constantly evolving 
international life science market. Extant literature suggests that international-oriented 
companies should carefully manage, organise, and control their outward and inward-
oriented activities if they are to succeed (Freeman et al., 2013). Zahra et al. (2000) and 
Roudini et al. (2012) collectively agreed that in transient markets, the ability to acquire 
product-related knowledge, customer requirements and the strategic positioning of a 
company can be important determinants of prosperity. Chetty and Wilson (2003) go as far 
as suggesting that developing productive networks in international markets assist SMEs and 
new firms to overcome early resource constraints (Teece et al. 1997) resulting from 
liabilities of smallness or newness (Aldrich and Auster, 1986).  In that sense, it can be 
expected that the marketing and commercialisation methods adopted by born global bio-
enterprises positively or negatively impact their success in international markets. As such, 
the key questions to be addressed in this research are as follows:  
(1) Which specific marketing and commercialisation arrangements do born global bio-
enterprises adopt with a view to achieve economic prosperity in international 
complex biotechnology markets? 
(2) How do born global bio-enterprises mitigate their smallness, newness and resource 
deficiencies in sophisticated international markets for successful marketing and 
commercialisation?      
The research questions outlined above are answered in this study by examining multiple 
cases of British born global bio-enterprises selected from the UK’s East Midlands region. 
The sample cases consist of two university and three technology-based spin-off firms. 
Nordman and Melén (2008) explained that university spin-offs are established by academic 
researchers who develop an innovative product from their work in a lab while Dahlstrand 
(1997) maintained that technology-based spin-off firms’ initial service idea originate from the 
previous employment of the founders. Notwithstanding their origins, this study defines the 
selected companies as born globals consistent with the views of Oviatt and McDougall 
(2005a) who expressed that university and technology-based spin-offs often become born 
globals. The sampled new and young bio-enterprises became born globals because of the 
market conditions in the UK’s East Midlands region. The region has a high concentration of 
biotechnology firms (Smith and Ehret. 2013) described in Brassington and Pettitt (2006) as a 
saturated market. Additionally, the internationalised configuration of the life science sector 
itself propels new entrants to seek international market opportunities elsewhere.  
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Kocak and Abimbola (2009) pointed to the speed and the rate at which the technology-
based industries emerge, transform and evolve as another push factor. As such, a look into 
the marketing and commercialisation strategies and tactics of born global bio-enterprises 
will exact our understanding of the intricacies of their international marketing management 
arrangements in such chaotic and unstructured global life science markets.   
2. Literature review 
Entrepreneurial born global companies have multiplied their presence beyond their 
proximity in search of strategic marketing and commercialisation capabilities. The companies 
have engaged in communities of economic co-operation and co-ordination with a view to 
market and commercialise their services with sufficient intensity. Tolstoy and Agndal (2010) 
explained that collaborative and partnership networks have become a key strategic 
manoeuvre that businesses use to broaden their scope and direction by exploiting the 
capabilities they offer. In Knight and Cavusgil (2004) the convergence of international 
markets was singled out as the push factor contributing to the establishment of integrated 
exchange systems allowing firms, regardless of their age, experience, and resource base to 
actively participate in the international marketplace. Noticeably, born global firms are 
increasingly embracing a co-creation approach enabling them to bridge their knowledge gaps. 
According to Lewin et al. (2009) this has permitted them to be efficient and to perform 
better because they are able to tap into global talents and resources. Existing research is 
littered with examples of entrepreneurial biotechnology companies which have utilised 
international marketing management strategies to broaden their presence in international 
markets (see for example Liebeskind et al., 1996; Gurău, 2002; Konde, 2008; Lindstrand et 
al., 2011; Simba, 2013). Their studies positively identify pro-activeness, flexibility and the 
collaborative propensities of biotechnology firms as the main characteristics that have 
enabled them to adapt their business models to withstand rapidly changing market 
conditions.  
Similar views are articulated in Tahvanainen and Steinert (2013); Mariussen and Ndlovu 
(2012); Carayannis (2009); Ghoshal and Nahapiet (1998) who all observed that by adapting 
innovative business models, entrepreneurial companies will be well-positioned to take 
advantage of, or to exploit social capital embedded in their networks. Zucker et al. (1998), 
Gartler and Levitte (2005) collectively acknowledged that entrepreneurial companies benefit 
from international collaborative networks. Keegan (2014) maintains that born global 
companies are beneficiaries of integrated international marketing channels. Consistent with 
this, Gabrielsson et al. (2008) explained that born-global firms rely on an intricate 
combination of collaborative networking, knowledge and outsourced expertise to boost 
their international business prowess. Indeed, modern day born-global firms are dynamic; 
they constantly re-invent themselves to mimic the ever-changing international business 
environment that they operate in (Freeman et al., 2013).  
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The literature (see for example Freeman et al., 2013; Simba, 2013; Kuivalainen et al., 2012; 
Knight and Cavusgil, 2004; Powell, et al., 1996; Oviatt and McDougall, 1994) universally 
acknowledged that by tapping into established networks and business-like relationships, 
born global firms have an opportunity to leapfrog beyond their limitations and access cutting 
edge resources and market opportunities internationally. Synthesising the debate on born 
globals, it appears that these entrepreneurial companies adopt sophisticated marketing and 
commercialisation strategies which have thus far, been difficult to contain in simple 
traditional marketing models. Therefore, the complexities of the approaches they have 
adopted especially in the biotechnology industry have necessitated the need to develop a 
more nuanced marketing model to adequately explain this new phenomenon. 
2.1 The operationalisation of the born global concept 
The literature is littered with different definitions of what born globals are. For example, 
Oviatt and McDougall (1994) define them as international new ventures (INVs) that seek to 
derive competitive advantage from the use of resources and the sale of outputs in multiple 
countries. Other scholars (see Knight and Cavusgil, 1996; Jones, 1999) use a variety of 
measures for defining these international new ventures such as: the vision and strategy to 
become global, time of internationalisation and overseas sales volumes. Scholarship on 
international entrepreneurship appears to use the term born global interchangeably to 
describe the born global companies and/or INVs. Madsen (2013) explained that there is 
however, some acknowledgement among different scholars on the theoretical delineation of 
the different views on the born global/INVs concepts, but the differences arise when it 
comes to their operationalisation. These potential differences have been somewhat 
addressed by scholars. While others have agreed that this has been the case others 
maintained that born globals and INVs do exhibit different characteristics (Crick, 2009). In 
Crick (2009) born globals are conceptualised as companies that have a global foci achieving a 
10% turnover in each of the triad’s three regions (i.e. USA, Japan and EU) whereas INVs 
were viewed as having an international objective to achieve 30% in their first three years of 
trading. Considering the different labels used to define born globals a distinguishing feature 
in all their delineations is that, they adopt a global strategy evidenced by their structural 
dimension which encompasses various actors in multiple countries (Oviatt and McDougall, 
1994). Equally important to this discourse Oviatt and McDougall (2005a) suggested that 
there is evidence which points to the fact that high-tech companies often become born 
globals. Notwithstanding this observation, there is still no universal agreement to a single 
definition of born-globals. In all the confusion and misconceptions regarding their 
conceptualisation, this study adopts a commonly applied (Gurau, 2010) definition of born 
globals which draws attention to the fact that at least 25% sales of a typical born global 
company should come from outside its home market in the first three years of inception 
(see for example Freeman et al., 2013; Gabrielsson and Kirpalani, 2012; Oviatt, and 
McDougall, 2005b; Knight and Cavusgil, 1996). Perhaps the last word on this debate can be 
left to Ferreira et al. (2010). Ferreira and others explained that irrespective of the label used 
to define born global companies they have to exhibit a clear trend indicating the 
commercialising of products or services on a global scale.  
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2.2 Entrepreneurial marketing and bio-enterprises   
Since the 1980s, the concept of entrepreneurial marketing has become a topical issue in 
relation to the way entrepreneurial companies design their marketing strategies. 
Entrepreneurial marketing is a term used in Al-Manasra et al. (2013) to describe the 
marketing processes adopted by firms which pursue opportunities in chaotic and 
unstructured market conditions such as those offered by the life science sector. An 
interesting perspective to entrepreneurial marketing is discussed in Hallback and 
Gabrielsson (2013) who argued that innovative marketing strategies which involve inter-
functional co-ordination significantly add value to entrepreneurial firms in turbulent market 
conditions. Related to this view, Al-Manasra et al. (2013) maintained that anticipating change 
is the core activity of an entrepreneur as it enables him/her to take advantage of his/her 
networks with minimum financial resources and restrictions on the time to engage in 
market research. Morris et al. (2002, p.8) cogently argued that “the proactive identification 
and exploitation of opportunities for acquiring and retaining profitable customers through 
innovative approaches to risk management, resource leveraging value creation” are central 
to entrepreneurial companies. Consistent with this, Mort et al. (2012) pinpointed four key 
strategies underpinning entrepreneurial marketing comprising: opportunity creation, 
customer intimacy-based innovative products, resource enhancement and legitimacy. 
According to Gabrielsson (2005) international new ventures use brand partnerships with a 
view to create marketing synergy.  
It is however essential that when discussing the entrepreneurial predispositions of born 
global companies an understanding of the concept of international entrepreneurship is also 
developed. McDougall and Oviatt (2000) described international entrepreneurship in a 
border sense as a “combination of innovative, proactive and risk taking behaviour that 
crosses or is compared across national borders and it is intended to create value in the 
business” (p.903). Furthermore, Oviatt and McDougall (2005a) conceptualised international 
entrepreneurship as “the discovery, enactment, evaluation, and exploitation of opportunities 
across national borders to create future goods and services” (p.540). An important point 
arising in Oviatt and McDougall (2005b) description of international entrepreneurship 
relevant to this study is that of studying the actions of organisations that take advantage of 
international trade and the impact of their engagements. In other words this research is a 
study of international entrepreneurship. Related to this, there is evidence in the extant 
literature indicating that much effort has been directed towards studying international 
entrepreneurship by various scholars. Indeed, this demonstrates the theoretical link 
between entrepreneurship and international business (see for example Hisrich et al, 1996; 
McDougall and Oviatt 2000; Dana, 2004; Wright and Ricks, 1994). Quite clearly, 
international entrepreneurship research has mirrored research on strategy and at the same 
time combining international business and entrepreneurship to explain complex 
organisational manoeuvres in international markets (Zahra and George, 2002). Based on this, 
our attention was drawn attention towards exploring the international entrepreneurial 
strategic approach of a specific category of high technology-based enterprises – bio-
enterprises identified as born globals for the purpose of this study.   
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2.3 The commercialisation strategies of bio-enterprises 
The life science industry has witnessed a marked rise of financial investments in 
technological entrepreneurship (Schilling, 2010). This has partially contributed to the 
proliferation of small, nascent firms developing inventions and technology with considerable 
commercial application (Gans and Stern, 2003). Research has shown that commercialisation 
is at the centre of strategy formulation and the success of research-intensive companies 
(Kascha and Dowling, 2008; Rothaermel and Deeds, 2004). Gans and Stern (2003, p.335) 
explained that “for many technology entrepreneurs, the commercialisation stage is the first 
opportunity to truly define a firm’s strategy and positioning”. Teece (1986) explored the 
determinants of a commercialisation strategy. He pointed out that firms need to develop 
complementary assets such as product development, production and marketing for 
successful commercialisation. Furthermore, Teece (1986) proposed a framework for 
developing complementary assets that assist in successful commercialisation. The model 
illustrates that firms can choose to develop their assets in-house or to co-operate with 
other companies with a view to access complementary skills. In science-intensive sectors 
such as the biotechnology industry co-operation occurs in different ways; ranging from 
arm’s length market transactions to equity-based co-operation (Shan, 1990), and via 
outsourcing arrangements (Roudini et al., 2012; Teece, 1986). In Kasch and Dowling (2008, 
p.1766) co-operation is regarded as, “an intermediate form of integration and market 
transactions”. The biotechnology industry is characterised by extensive co-operation 
between diverse agents that include established pharmaceutical companies, investors and 
government agencies (Rafols et al., 2012). It therefore, follows that to commercialise a new 
drug, a young biotechnology firm would require complementary assets such as specialised 
labs for production, as well as marketing expertise (Kasch and Dowling, 2008). From that 
perspective, this study aims to investigate how born global bio-enterprises mitigate their 
newness and resource deficiencies in sophisticated international markets for successful 
marketing and commercialisation thereby contributing to the concepts of international 
marketing management. 
2.4 An overview of existing theories 
 Existing studies treat commercialisation (Conceicao et al. 2012; Kasch and Dowling, 2008) 
and entrepreneurial marketing concepts (Al- Manasra et al., 2013; Eriksson and Rajamäki, 
2010; Huck and Rennhak, 2013; Hallback and Gabrielsson, 2013; Gans and Stern, 2003) 
separately. This does not reflect the specific entrepreneurial marketing management and 
commercialisation arrangements of born global bio-enterprises. From that point of view, this 
study combines the two operational strategies mentioned above with empirical evidence. 
The duality informs the development a theoretical model (presented on p.19) which 
adequately explains the activities of born global bio-enterprises exhibiting a clear trend of 
entrepreneurial marketing management and commercialisation of products or services on a 
global scale.            
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3. Research Methodology 
3.1 Methodological approach and case selection 
The main purpose of this research study is to propose new theory concerning the 
marketing and commercialisation arrangements of born global bio-enterprises. As such, the 
authors of this article deemed the qualitative multi-case strategy to be an appropriate 
methodological approach. Context was considered to be vital because it helps to 
understand their specific marketing and commercialisation arrangements. Therefore, to 
strengthen the development of theory and propositions the study utilised multiple cases (Yin, 
2003; Gerring, 2005). Furthermore, a co-ordinated research approach of induction and 
deduction described as abduction in Saunders et al. (2012) was adopted enabling the study 
to benefit from the use of existing theory and to critically examine empirical evidence. The 
duality allowed the study to develop an in-depth understanding of the entrepreneurial 
abilities of bio-enterprises and to establish casual explanations (Miles and Huberman, 1994) 
between their entrepreneurial predispositions and marketing arrangements in their 
communities of economic co-operation and co-ordination (networks). The criteria for 
selecting cases was purposeful and it was based on theoretical sampling (Patton, 1990). The 
cases were chosen on the basis that similar results were predicted to be produced within 
each case – a process termed literal replication in Yin (2009).  
After establishing a sample selection strategy, BioCity Nottingham (BCN), Enterprise 
Europe Network (EEN), Pera Innovation Network (PIN), Loughborough Innovation Centre 
(LIC) and Medilink databases were used to identify suitable biotechnology companies. 
Appropriate cases were classified using the following criteria: (1) an enterprise had to 
conform to a commonly used definition of born globals which accentuates that at least 25% 
of their sales had to come from outside their home market in the first three years of their 
inception (see for example Gabrielsson and Kirpalani, 2012; Oviatt, and McDougall, 2005b; 
Knight and Cavusgil, 1996). (2) The enterprises were also expected to use the East Midlands 
region as their home market. The logic underpinning this classification was that the region 
has a high concentration of University and technology-based spin-offs. The study considered 
research activities at BCN, LIC, Nottingham Trent University, University of Nottingham, the 
University of Leicester, Loughborough University and AstraZeneca’s re-organisation as the 
key factors contributing to the formation of small biotechnology companies in significantly 
large numbers. This was presumed to have led to market saturation, forcing the 
biotechnology companies under investigation to consider international markets. (3) The 
firms had to use scientific knowledge for new drug discovery services and technical know-
how to assist their clients to develop new clinical processes. (4) The companies had to be 
involved in communities of co-operation and co-ordination both domestically and overseas. 
(5) Well-established biotechnology companies were excluded from the sample because of 
their tendency to develop less flexible structures. The criteria set above for selecting 
companies led the study to five born global bio-enterprises (see an overview of the 
companies in Table 1 on p.8).    
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Table 1: An overview of sampled born global bio-enterprises 
  
Company A 
 
Company B 
 
Company C 
 
Company D 
 
Company E 
 
Year of registration 
 
 
2002 
 
2011 
 
2004 
 
2010 
 
2003 
                     Location BCN East 
Midlands 
 
BCN East 
Midlands 
BCN East Midlands LIC East Midlands BCN East 
Midlands 
        Trade description Manufacture of 
pharmaceutical 
preparations 
Research and 
experiment 
development on 
biotechnology 
 
Integrated drug 
discovery services to the 
pharmaceutical and 
biotechnology market 
Scientific and 
technical activities 
in biotechnology 
Research and 
experiment 
development on 
biotechnology 
Company size (2013) Micro/small  Micro/small 
 
Small Micro/small Micro/small 
        No of Employees 13 9 
 
69 6 6 
            Total turnover  £618,315 £124,962 
 
£6,951,533 £300,681 £163,616 
Overseas sales in year 
3 (2013) 
 
£381,348 
 
£86,642 
 
 
£2,244,018 
 
£165,884 
 
£61,742 
% Overseas sales 61% 69% 
 
32% 55% 37% 
Overseas partnerships 4 in the USA 
and Europe  
6 in the USA, 
Canada, India and 
China 
3 in  North America and 
Europe 
2 in America and 
Europe 
2 in China and 
the USA 
 
3.2 Data collection and analysis 
In order to improve the quality of the conceptualisation or operationalisation (construct 
validity) of the main theories the study utilised a range of sources of evidence and methods 
of analysis. Specifically, primary data was collected from key informants in each company 
who included: CEOs, business development officers (BDO) and senior scientists. To 
corroborate the accounts given by the participants, 30 face-to-face interviews were carried 
out lasting between 105 to 150 minutes with an average duration of 115 minutes. In each 
case, 4-6 interviews were carried out to increase the reliability of the data to be collected 
for analysis (Eisenhardt, 1989; Huberman and Miles, 1994). To ensure consistency and 
validity of collected data the same semi-structured questions were used to guide all the 
interviews. The interviews were audio-recorded and subsequently transcribed. Additionally, 
secondary data materials were accessed using company databases, Companies House and 
publicly available literature. Follow-up emails and telephone calls were made in instances 
where additional information was required. The credibility of the information collected from 
the key informants was enhanced when the study reached a point of saturation i.e. a point 
where the participants were giving previously presented events. At that stage no further 
interviews were deemed necessary (Riley, 1996). Following data collection the next stage 
was to analyse the data. Within case analysis was carried out and a descriptive write-up 
(Pettigrew 1988) of each case was done in order to develop a rich and in-depth insight into 
their international marketing activities. Following this, a cross case synthesis (Yin, 2003) was 
done to identify patterns of their marketing management activities.  
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At the data analysis stage a thematic technique was used. Both researchers were involved at 
the data collection stage and its analysis and in identifying the key themes emanating from 
the literature and the empirical findings (Bellamy and Perri, 2009). The main goal was to 
increase the reliability, credibility and the strength of the inferences of the research – a 
process described in Denzin (1970) as investigator triangulation, which refers to the use of 
more than one researcher in the field to gather and interpret data. The analytical tool used 
in this study is termed explanation building (Gray, 2014). The idea for using this analytical 
technique was to develop a frame to assist in explaining the components that were 
considered to be associated with the entrepreneurial marketing and the commercialisation 
strategies of born global bio-enterprises. In that sense, our aim is to analyse the 
entrepreneurial marketing management and commercialisation strategies of the sampled 
companies. Concomitant with this activity, the study made theoretical propositions.                  
4. Empirical Findings 
This part of the study presents the research findings detailing the marketing and 
commercialisation strategies and tactics of born global bio-enterprises outlined in Table 1 on 
p.8.    
4.1 Company A 
To export its pharmaceutical preparations company A relied, to a great extent, on 
collaborative networks established in the US and Europe. The biotechnology company 
followed a cost-effective intermediary system whereby it licensed its products/services to 
international health ventures. As part of the arrangement the entire financing package for 
the project was funded by the venture. The bio-enterprise benefited from this 
commercialisation arrangement by receiving marketing advice, assistance, royalties and R&D 
investments to fund its new drug discovery projects. This assisted the bio-enterprise to 
reach product development milestones. The company’s CEO gave more insights into the 
benefits of its marketing and commercialisation arrangements stating that: 
We acquire marketing, pharmaceutical-related expertise, PR, and financial support from our 
business partners to back our products and these are things that we do not have in-house 
and they are necessary to achieve our goals  
The company’s international entrepreneurial strategy was reflected by its participation in 
international conferences designed to bring together a diverse science community of 
biotechnology companies and special-interest groups. The bio-enterprise was effective in the 
way it used its communities of economic co-operation and co-ordination for its commercial 
reasons. This is reflected in the quotation below: 
The use of university expertise for imaging drug deposition and clearance will greatly enhance 
the development of this formulation (teriparatide formulation). This project will draw on inter-
disciplinary collaborative research from international experts and EU funding. (BDO)   
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In a related discussion on marketing and commercialisation strategies in biotechnology, with 
a senior scientist, also involved in developing strategic partners for the biotechnology 
company, echoed similar sentiments:  
……..often than not you find that in these internationalised biotechnology markets if you 
want to publicise your innovations you find yourself talking to another company in another 
part of the world.     
The bio-enterprise appeared to select partners with a strategic fit for commercial reasons. 
Its BDO explains this more fully:  
We travel worldwide for example; we attend seminars in the USA, and in Europe seeking for 
partners with complementary commercialisation capabilities. We engage with global networks 
to access crucial market-specific information which we feel is important for our business. Our 
product is unique and we do not have any other companies within the East Midlands which 
complement our services so we venture to countries such as the US and to countries in the 
EU.     
To guarantee the marketing success of its pharmaceutical preparations the biotechnology 
company preferred to enter into collaborations with partners who were committed and 
were successful/established pharmaceutical companies. The partnership selection process 
was meticulous and it was based on product compatibility, reputation, technical know-how, 
marketing management expertise and financial soundness. Irrespective of the fact that the 
drug will succeed, the company initiated its commercialisation process during a drug’s 
transition period using a partnership approach. According to the company’s BDO the idea 
behind what he termed ‘early commercialisation’ was to… 
….test the commercial potential of our compounds early in the drug development process. 
We are aware that market and regulatory forces could change in the time required to bring 
our product from pre-clinical testing to launch therefore, this early process which involves our 
strategic business partners and clients reduces the time to market.    
The companies selected through this commercialisation arrangement were either directly 
involved in human drug development or they were key stakeholders in biotechnology. The 
underlying motive was to accelerate the commercialisation of its developments on an 
international scale; table 1 on p.6 illustrates a significantly high percentage (61%) of overseas 
sales as a fraction of the company’s total revenue for 2013. This demonstrates that the 
international marketing and commercialisation arrangements of the bio-enterprise were 
achieving the desired effect. 
4.2 Company B 
Although company B is the newest in the research sample, it entered the market with a 
highly structured international distribution system designed to reduce time to market. In the 
US the company was quick to establish a distribution channel through a business partner in 
San Diego California.  
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Using a piggybacking marketing arrangement with its San Diego-based partner the bio-
enterprise was able to provide its US-based clientele with drug metabolism and 
pharmacokinetics (DMPK) services from an early stage of drug discovery through to its 
development. The CEO of the company was clear about how his company and its clientele 
were benefiting from the piggybacking marketing strategy. This is what he had to say:  
Our collaboration combines state-of-the-art in vitro, in vivo and bio analytical capabilities with 
our expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation. This integrated 
approach provides clients with the information required to successfully achieve their drug 
discovery and development goals. 
The chief scientist of the bio-enterprise reaffirmed similar views when he explained that:  
Our combined consultative approach to problem solving provides our overseas clients with 
increased flexibility, focused data, high content and quality and ultimately time and cost 
savings.   
The company’s piggybacking strategy was a very effective way of utilising its international 
channel systems. Its selected strategic business partners were presumed to be not in direct 
competition with the bio-enterprise. Nonetheless, the companies were chosen on the basis 
that their services appealed to the same type of customers and that they complement the 
company A’s drug metabolism and pharmacokinetics (DMPK) services. Based on its 
common approach with its business partners, an agreement was reached in 2011 with its 
San Diego California-based partner to cover the shipping costs of its science compounds to 
its US first-time clients. To this end, its US-based partner commented that:  
…….is located in the UK and we are offering to cover the cost of shipping compounds for 
first time clients. We work with reliable couriers that are able to deliver compounds to clients 
quickly and cost-effectively.   
The piggybacking strategy was not only applied in the life science sector in the US alone. 
The enterprise had a wide network of established pharmaceutical companies/clients in the 
Far East, UK and Europe. Its BDO elaborated this view and expressed that:  
We are an international contract research laboratory-based business. We carry out tests on 
research compounds to ensure that they have suitable metabolic stability in ‘vitro’ for our local 
and international clients. We collaborate on an international scale with companies in the 
China, India, Canada, Europe and the US to ensure our services satisfy the development 
needs of clients’ metabolism and pharmacokinetics processes. 
The company identified and recruited its business partners by engaging in purposefully 
designed international conferences.  
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Its networking strategy for marketing and commercialisation was deliberate and it was 
intended to take advantage of the resources embedded in its strategic partners (usually 
reputable pharmaceutical companies) established in world-renowned science networks of 
biotechnology such as Boston’s biotechnology metropolitan area, Massachusetts Institute of 
Health Science and Cambridge’s network of networks. This was explained more fully by the 
company’s CEO in the quotation below:  
Working in partnerships and collaborative projects in ‘open science’ networks with our US 
and British counterparts increases our level of commercialisation and it considerably bridges 
the gap between our internal capabilities and the threshold level required to penetrate 
overseas markets. We also benefit in terms of low operational costs from our strategic 
partners and from those partners who have a good reputation especially, those business 
partners who are part of well-developed networks such as Boston, Medicon Valley, MIT and 
the Golden Triangle of Cambridge, London and Oxford we get access to their markets and 
marketing expertise.   
The company’s top management team attended bio-science events to access cutting edge 
resources and market opportunities. A look into their itineraries revealed that they 
routinely booked to attend events organised by Bio-Europe; a deliberate international 
partnering conference usually convened in European countries. Attending such events was 
seen as an on-going marketing strategy by the enterprise. The BDO of the enterprise 
commented that:  
Having attended the BioSpain conference in September of 2012, our plan is to build more 
connections with like-minded companies and seek further partnering opportunities 
As part of attending conferences such as BioSpain, the top management team presented its 
laboratory research findings. This was a company-wide international marketing strategy 
designed to publish its research findings following successful lab tests. The ultimate goal was 
to reach out to a large clientele as well as attract commercial partners (both small and large 
pharmaceutical companies). The company’s overseas sales percentage of 69% illustrated in 
table 1 on page 7 demonstrates the impact of its international entrepreneurship and 
marketing predispositions.    
4.3 Company C 
In the second year (2005) of its establishment, company C was pre-occupied with identifying 
foreign distribution channels and production partners experienced in the commercialisation 
of Pharmix technology. Its business idea was to work in partnerships with established 
pharmaceutical corporations with a view to breakthrough into international markets. The 
president of the enterprise expressed the view that: 
………..is well placed to take advantage of the increasing opportunities presented to it by 
this globalised pharmaceutical industry.  Drug discovery and development is an expensive and 
time-consuming process, the chances of successfully producing a new marketed drug remain 
small, and the industry is going through an unprecedented period of change and uncertainty. 
13 
 
In the face of these challenges, as we undertake pharmaceutical R&D we require, more than 
ever trusted strategic business partners, regardless of their location, with extensive industry 
experience to accelerate our drug discovery services as well as increase their commercial 
value. 
The remarks above give the impression that company C’s marketing efforts were fixated on 
developing effective commercialisation arrangements with a determination to add value and 
extend the range of its services far and wide. In 2008 the bio-enterprise entered into a trade 
agreement with a German-based pharmaceutical company which provides protein-structure 
accelerated drug discovery services to more than 80 pharmaceutical and biotechnology 
clients in North America, Europe and Asia. Establishing a business-like relationship with a 
company that has such a large pool of clientele allowed the bio-enterprise to broaden its 
customer base while, offering a standardised drug discovery service. Furthermore, this 
commercialisation arrangement was seen by the  CEO of the enterprise as a crucial 
undertaking of enhancing customer value as his company was able to provide its clientele 
with an integrated drug discovery service both domestically and internationally. When asked 
about the importance of establishing partnerships to his bio-enterprises’ marketing and 
commercialisation strategy, its CEO explained that: 
With the addition of ……… to the ‘federated’ CRO Model, it enables us to offer our 
customers a world class, fully-integrated drug discovery service which would allow us to design 
novel compounds, synthesise and screen in vitro. The X-ray protein structure analysis 
undertaken at ………., metabolic liability and toxicity assessed at ………. and then tested 
at ………..and ………. in pharmocodynamic and disease-relevant models.  This powerful 
federation of alliance partners will help accelerate our clients’ drug discovery programmes 
towards development. 
At the beginning of 2013 the bio-enterprise was selected to be one of Europe’s seven Lead 
Factories of molecule data supported by Innovative Medicines Initiatives (IMI). The IMI’s role 
was to build a library of science compounds accessible to both private and public 
organisations offering promising new targets for drug discovery screening. This presented 
the bio-enterprise with an opportunity to publish and attract potential clientele for its drug 
discovery services. In addition to its use of an open European science library, the company 
also used online marketing. From time to time, it emailed a newsletter/magazine to its 
customers and the science community highlighting new developments in terms of drug 
discoveries or ground breaking lab test results, more so, it’s newly acquired science 
capabilities. This enhanced its brand image and reputation. These were the key success 
factors which enabled the company to accelerate its growth in Europe and the US. In a 
conversation we had with the CEO of the bio-enterprise regarding its recent strategic 
alliance in Europe, he commented that: 
…….has specialist skills in early stage drug discovery that are highly-complementary to our 
own. We tap into their outstanding reputation for providing unique and best-in-class 
technologies to broaden our client base.   
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Most of the alliances that were developed by the company were in the form of partnerships 
intended to facilitate R&D, distribution, marketing and to establish brand credibility. As such, 
developing complementary business partners in Europe and the US enhanced company 
performance and boosted its revenues as evidenced by figures illustrated in table 1 on page 
6 showing that almost a third of its revenue was generated from overseas in their third year 
of trading.          
4.4 Company D 
The company’s marketing and commercialisation strategy was mainly driven by its owner. 
During the first few years of its formation the company appeared to aggressively pursue 
collaborations and partnerships in multiple countries. It positioned itself in the 
biotechnology markets as a consultancy firm working on contract basis. For its marketing; 
presentations at seminars were used as the main media for communicating with potential 
clientele. Specifically, the bio-enterprise adopted a direct marketing approach which was 
mainly anchored on its founder who stated that:      
I personally have social relationships with people who I have known for a long time. I have 
some contacts in America where my business started way back in 1998 as a model based on 
a drug development firm. I still communicate directly with firms I did consultancy work for 
and friends in the USA and in Europe informing them of how our technical capabilities have 
evolved – basically I will be bidding for more work. I also engage with a number of scientists 
at our annual meeting code named PAGE. (Company D CEO and Founder). 
The company’s website was also used as a powerful marketing tool – communicating 
information about the enterprises’ science capabilities. The experience in life science of key 
team members is publicly available on its site. This marketing technique was used to attract 
pharmaceutical companies who use consultants with a proven record in Pharmacometrics and 
PKPD modelling and simulation to outsource their drug testing/development services. 
Before the company relocated to Loughborough from Nottingham, its preferred approach 
for creating publicity was through research syndicates. Such alliances were part of the 
company’s marketing campaign for advertising its science capabilities. Specifically, they were 
used as a showcase of its science modelling and simulation capabilities in the process of 
developing life-saving drugs to treat malaria and poverty-related diseases in under-developed 
nations. The founder and CEO of the business claimed that the marketing strategy which 
was designed to enhance his enterprises’ reputation worked well. This is how he put it: 
This way of doing business brought significant benefits to our company associated with 
credibility and reputation which are essential for contract research organisations such as ours. 
I was motivated to continue pursuing alliances of this type (research syndicates) because I 
realised their value to us. The malaria consortium was pivotal to our international strategy 
and it significantly assisted our economic development and growth.         
Interestingly, when the company relocated in 2012, a knowledge transfer partnership (KTP) 
approach was adopted as a commercialisation strategy for company-based capabilities and 
for marketing purposes.  
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The BDO of the enterprise stated that:  
We are interested in collaborating with universities and computer firms to jointly develop 
simulation mathematical combinations. This cross fertilisation is important in the sense that it 
enables us to develop what we intend to produce. We have established these partnerships in 
Europe and the US where …….initially traded as a consultancy.    
To engage in extensive promotion and marketing of its human drug services the enterprises’ 
CEO put it this way:  
The conference we usually attend in Glasgow hosts a large pool of scientists, health 
professionals, academics, MHARA (to do with authorising new medicines). This makes it more 
worthwhile for us to attend in the sense that we are in a position to access vital market-
specific knowledge and information essential for marketing our consultancy work. 
The enterprise’s entrepreneurial marketing moves were well complemented by the 
marketing infrastructure created by these huge science community assemblies guaranteeing 
brand recognition and endorsement.      
4.5 Company E 
Company E distinctly developed a customer-centered marketing approach – a point made 
clear by its CEO who remarked that:  
There is a real need for rapid acting, ready-to-use haemostats that are safe and cost-effective, 
and we believe our technology can deliver these benefits to surgeons and their patients  
The enterprise employed an innovative marketing strategy. Through its trade agreement 
plan, the enterprise increased its involvement by forming long-term partnership-based 
relationships. The enterprise’s trade agreements typically involved the negotiation of equity 
investment and the co-promotion and co-marketing of its technology, allowing it to 
generate a steady stream of revenue. Its network of trading partners was dominated by 
companies which provide investment funds and grants as well as mobilise research, 
networks and skills. When discussing about the role of external funding to his enterprise’s 
technology development process, its CEO explicated it this way: 
Funding is vital to the continued development of our technology. Last month we received a 
significant financial injection to back our clinical development of new haemostat to control 
surgical bleeding. This Award and the share-holder investment will enable us to generate 
more data to support the translation process from research to patients.  
In addition to R&D funding it received; its investors contributed, business management and 
marketing experience, and they brought networking contacts which added considerable 
value to the bio-enterprise and its clientele. As a university spin-off, the company used 
university bulletins to publish its research activities with the intention to attract funding and 
potential investors and to gain credibility. The same platform was used to inform its 
targeted audience (doctors, nurses and surgeons) about the importance of its technology to 
the work they do.  
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This marketing technique was being used by the enterprise to boost its reputation and 
credibility. The enterprise also used niche marketing as a tactic to lure investors by 
demonstrating that its technology matched a specific market need. This enabled the bio-
enterprise to attract more funding. Commenting on the financial agreement to fund 
company E’s technological development, the head of business development of an investing 
company pointed out that:  
Improved control of bleeding is vital for safe and effective surgical procedures. We are 
pleased to offer our continued support to this project and look forward to seeing the 
technology advance towards clinical use 
The bio-enterprise maximised its marketing economies of scale by taking advantage of its 
investors’ online presence. The enterprise also used its own online presence to inform 
potential partners and clientele about its science capabilities and the cumulative experience 
of its founder and the top management team. 
4.6 Cross-case analysis  
In this section, the research analyses the marketing and commercialisation strategies and 
tactics of all five born global bio-enterprises, particularly, focussing on how the strategies 
and tactics were executed, managed and organised. Using cross-case analysis enabled the 
study to map out the marketing and commercialisation strategies of all the companies. This 
process involved the use of secondary data and empirical evidence obtained from each born 
global bio-enterprise. The study constantly compared existing theory and data from the 
research sample, iteratively moving towards a close fit between the two (Gray, 2014).  
The ultimate goal was to identify any emerging patterns that would assist theory formation 
regarding international marketing management and international entrepreneurship in born 
global bio-enterprises. Synthesising themes identified in the literature and data collected 
from cases of born global bio-enterprises (as illustrated in table 2 below) indicated that they 
use various marketing and commercialisation methods in the internationalised biotechnology 
sector. The study found that irrespective of the origins of the studied bio-enterprises 
(whether university or technology-based spin-off) they appeared to follow an identical 
marketing framework. In all the cases there was evidence of entrepreneurial marketing 
predispositions. The standardisation of the elements of the marketing mix specifically 
promotion, distribution and services was crucial to how they established their brands 
domestically and in overseas markets. Marketing mix standardising was achieved through the 
formation of strategic alliances in multiple countries. In view of this, it is plausible to suggest 
that standardising components of the marketing mix is an appropriate strategy to follow in 
international markets (Brassington and Pettitt, 2006). Evidently, during their first few years 
of operation the companies were quick to search for complementary partners which they 
used as conduits for their marketing activities while at the same time tapping into their 
commercialisation capabilities. Partnerships, trade agreements and networking enabled the 
companies to enjoy economies of scale. These methods of marketing and commercialisation 
particularly facilitated low-cost marketing (co-promotion and co-marketing) and shared 
R&D risks. 
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Table 2: Biotechnology marketing and commercialisation arrangements  
 
    Standardised marketing and commercialisation arrangements  
 
 
 
Bio-enterprise 
initiatives  
Co-ordinated 
international marketing 
activities 
Commercialisation 
arrangements  
Distribution  
systems  
Market entry 
strategies 
                                           
Company A Seeks complementary 
capabilities locally and 
internationally. Taps into 
partners’ existing 
marketing channels, 
sponsors PhD researchers  
 
Presents at international 
bio-science events. Uses 
strategic partners and 
company website. Maintains 
relationship with science 
community at exhibitions  
 
Enters into research 
contracts (co-operative 
commercialisation) with 
established 
pharmaceutical 
companies in multiple 
countries 
 
Uses strategic 
partner’s service 
distribution 
channels. Also 
uses network 
contacts  
 
Licenses IP rights, 
strategic alliances, 
networks 
        
Company B 
 
Employs experienced 
scientists. Owner uses 
personal contacts as 
sources for capabilities. 
Takes advantage of 
partners’ marketing 
capabilities. Joint 
commercialisation 
 
Same as company A. Also 
uses trade magazines and 
contacts customers by 
emailing news bulletins. Co-
sponsored a booth at 
exhibition in the US. 
Participates in USA 
roadshows with its partner   
 
Same as company A. 
Also outsources drug 
discovery activities to 
strategic partners  
 
Same as company 
A 
 
Piggyback, 
networks, 
partnerships  
 
Company C 
 
Exploits partners’ 
customer base. Joint 
commercialisation and 
engages in collaborative 
R&D projects 
 
Contributes to a public 
European science library 
(brand building). Uses e-
science magazines. Joint 
publications in academic 
journals 
 
Same as company A.  
 
Uses partner’s 
service 
distribution 
systems 
 
Trade agreements 
with foreign 
companies, 
networks, strategic 
alliances 
        
Company D 
 
Personal contacts used for 
market intelligence, Uses 
knowledge transfer 
partnerships, Employs 
university graduates. 
Facilitates work 
placements   
 
Provides lectures at 
seminars, research 
publications, direct 
marketing, participation at 
conferences 
 
Part of a research 
consortium of 24 
companies.  
 
Uses previous 
contacts in the 
US, Italy and 
Switzerland.  
 
KTP, Academic 
partnerships 
         
Company E 
 
Has strong university 
links, Applies for research 
funding, Targets a niche 
market (operating 
theatres)   
 
Advertises in academic 
bulletins and a university 
website. Produces research 
publications   
 
Relies on Venture 
Capitalists (VCs), 
Charitable 
organisations, 
government institutions 
for funding to develop 
its technology  
 
Uses VCs 
contacts/networks 
for product 
distribution 
 
Trade agreements, 
Research contracts 
      
 
In the international marketing management literature (see Jeannet and Hennessey, 1995; 
Brassington and Pettitt, 2006; Doole and Lowe, 2012) partnerships are seen as an 
appropriate strategy that allow companies to join R&D forces with a view to develop a 
specific product, market, share a distribution channel and to sell each other’s product. The 
process of selecting business partners was also an important event for all the companies. 
The criteria for choosing partners were anchored on ‘strategic fit’. Specifically, it was based 
on product compatibility and distribution networks, synergy, marketing and financial 
soundness. In the first three years of their operations all the enterprises achieved more that 
25% of overseas sales (see table 1 on p.8). This suggests that their marketing management 
and commercialisation strategies and tactics were effective. This was possible because they 
were able to bring together complementary assets and skills using their entrepreneurial 
dispositions (Johnson et al., 2008; Schilling, 2010).  
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Company D and E had strong university links which they used for publishing their lab tests 
to the internationalised life science markets. Exhibitions, conferences and research seminars 
were used by all the companies as a platform for showcasing their science competencies. 
Science exhibitions were also used to target potential clientele and as an opportunity for 
opening up dialogue with identified business partners. Companies A, B and C used their 
founders’ personal connections to facilitate the distribution of their services. None of the 
companies established their own subsidiaries in the countries they had clientele, but rather 
they used their business partners as intermediaries, indicating that networking was the most 
preferred market entry strategy. External partners especially, VCs were identified as the 
most important agents which financially supported and enabled various marketing and 
commercialisation activities to occur in biotechnology. A major finding was that, in all the 
companies, their top management teams consisted of internationally recognised scientists 
with commercialisation and ‘deal-making’ experience in biotechnology. Some of the 
directors were even involved in more than two companies. Their wide links, expertise, and 
experience were subsequently used to provide the scope and direction for the bio-
enterprises, with a view to succeed in the often chaotic and unstructured international 
biotechnology markets.                
5. A new entrepreneurial marketing management and 
commercialisation framework 
As has already been mentioned in the study, born global bio-enterprises are involved in 
science-intensive markets, dealing with sophisticated technology, which makes it difficult for 
simple traditional marketing frameworks to adequately capture the detail of their marketing 
and commercialisation strategies and tactics in international markets. As such, this study 
proposes a new model designed to capture these phenomena more accurately. Developing a 
theoretical framework was a strenuous process. It involved a procedure whereby the 
researchers investigated the underlying facets of international marketing management in bio-
enterprises to understand the logical reasons for their chosen business approaches. The 
proposed theoretical framework uses the international marketing management literature 
and empirical research evidence. Many scholars agree that theory developed in this way is 
one that is imbued with merit (see Collier and Mahon, 1993; Gerring, 2001; Goertz, 2005; 
Bellamy and Peri, 2009). The study established a strong connection between born global 
bio-enterprises and extant literature permitting the formation of a testable, relevant and 
valid conceptual framework (Glaser and Strauss, 1967). The new frame of reference is 
presented in figure 1 below. The model demonstrates a deliberate and calculated process of 
clear internal skills appraisal, followed by efforts to identify relevant complementary skills 
and capabilities to enhance a bio-enterprises’ commercial and international marketing 
management acumen. Partnering strategies guaranteed better performance, customer 
satisfaction and improved sales revenues. The process encapsulated in the model is 
discussed, in detail, in the ensuing sections. The authors invite other scholars to further 
develop the proposed entrepreneurial marketing management instrument, so as to extend 
its applicability in marketing management.    
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Fig.1. A conceptual model of entrepreneurial marketing management and commercialisation 
in born global bio- enterprises 
5.1 Company-based marketing and commercialisation arrangements 
The studied bio-enterprises demonstrated a strong sense of clarity and self-awareness, 
beginning with a clear articulation of their aims and objectives from inception. This was 
overlain by an honest introspection and appraisal of their internal skills capabilities. With 
their core skills, competencies and capabilities now catalogued, the bio-enterprises 
seemingly built their core businesses around the identified core sets of skills. The initial 
company strategies were seemingly built around the skills and experiences of the business 
founders. They forged productive partnerships and often surrounded themselves with 
skilled scientists, university graduates and people with commercial skills usually contracted 
from local and international markets as and when required. After an internal skills appraisal, 
there appeared to have been a deliberate process of mapping available skills against the 
companies’ overall objectives, leading to a gap analysis. Thereafter, the newly developed 
model presented above suggests that born global bio-enterprises conducted an 
environmental scanning exercise aimed at identifying suitable skills and competencies that 
complement firm-based capabilities. It was crucial that the bio-enterprises built a set of 
specialist complementary skills to realise their objectives. There seemed to have been a 
two-pronged strategy of exploiting personal networks and contacts, on one hand and on the 
other hand, networks and/or commercial communities of co-operation were explored to 
identify and bring into the enterprise the required skills and competencies. In the literature 
about born global (see Gurău et al., 2010; Laanti, et al. 2007; Madsen and Servais, 1997; 
Sharma and Blomstermo, 2003; Oviatt and McDougall, 1994) there is near universal 
agreement that founders and the top management teams of born global firms use their 
experiences in science to assist their firms to acquire new capabilities and to successfully 
enter foreign markets.  
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Thus, the study proposes the following: 
Proposition 1: Business and personal connections of the founders and the top management 
teams perform an important function in born global bio-enterprises by providing them with scope 
and direction in the internationalised biotechnology markets.  
5.2 Bio-enterprise initiatives 
The studied bio-enterprises demonstrated an affinity for partnerships with universities and 
local science parks. This is consistent with Houlder (1995) who explained that strategic 
alliances can help an organisation to enter new markets, access expertise and technology 
and to achieve economies of scale much more quickly. A prominent characteristic of the 
studied bio-enterprises was that their initial marketing management, commercialisation 
strategies and tactics were customer-centered demonstrating their efforts to satisfy specific 
customer requirements. Engaging in collaborative programmes enabled bio-enterprises to 
access financial support, specialised laboratory equipment essential for R&D, drug testing 
and development equipment, critical scientific communities as well as multi-purpose built 
accommodation. This significantly reduced the time to market for them. There was also a 
prevalent use of direct marketing strategies whereby the companies’ and partners’ websites 
were used to showcase key staff capabilities, expertise and the organisations’ core 
competencies. Two of the bio-enterprises which had their origins in universities used their 
resources to foster further collaborations with a view to enhance their profiles. Where 
personal networks were exhausted, companies used local science parks and took advantage 
of government support. Born global bio-enterprises sought assistance from the government 
and established science institutions which often came with some input from science experts 
in the form of coaching.  
As such, the study makes the following proposition: 
 Proposition 2: The entrepreneurial predispositions of born global bio-enterprises enable them to 
identify knowledge gaps in their enterprises. As such, the implementation of entrepreneurial 
marketing techniques in the internationalised biotechnology markets is a tactical manoeuvre that 
assists them to bridge their knowledge gaps; access essential marketing and technical capabilities 
proclaim their existence and simultaneously establish their brands.  
5.3 International marketing and commercialisation arrangements  
The studied bio-enterprises were aggressive in the way they targeted business opportunities 
as a result of trade liberalisation in today’s international markets. A prominently strong 
feature of their strategies was their networking abilities in multiple countries – a view also 
expressed in Freeman el al. (2010); Rasmussen and Madsen (2002). Top management team 
members often attended international conferences, science seminars and other trade 
exhibitions. At these events, they publicised their laboratory findings and technological 
capabilities and they were also able to: (i) showcase their company’s services, science 
capabilities and to promote their services.  
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This was purposefully done in order to attract potential funding and/or commercial partners 
from an international audience, (ii) scan the market, to identify emerging science technology 
and to scout for potential distribution networks. Purposeful international marketing 
management and commercialisation arrangements ensued from these initiatives, primarily 
employing strategies such as piggybacking and licensing. This permitted the born global bio-
enterprises to benefit from the complementary assets of their strategic partners which 
provided them with synergy and marketing mix standardisation. By combining technological 
resources and marketing capabilities, the firms were able to expand their market knowledge 
and do so more rapidly than they would alone (Schilling, 2010). This study therefore 
proposes the following: 
Proposition 3: The liberalisation of international markets allows born global bio-enterprise to 
take advantage of the resources embedded in specialised science communities that transcend their 
immediate proximity. In such close-knit communities bio-enterprises are able to standardise their 
marketing and commercialisation strategies through partnership arrangements. Partnerships are a 
conduit which accelerates foreign market entry and brand development.  
5.4 Realised value 
The underlying motive for using various marketing management and commercialisation 
tactics in international biotechnology markets, by studied enterprises, was to first of all 
satisfy customer needs and secondly to do so profitably. In the literature (Oviatt and 
McDougall, 1994; Knight, 2000) a typical born global firm is conceptualised as having 
achieved at least 25% overseas sales in their third year of trading. The studied bio-
enterprises seem to have surpassed the threshold constantly referred to in the literature. 
The lowest achiever (Company C) made 32% overseas sales while the highest achiever 
(Company B) realised 69% overseas revenues as a proportion of their total revenue in the 
third year of their respective operations. These results are astounding, considering that the 
three years leading up to the reported trading period (2013) were characterised by a 
debilitating global recession where most firms reported a decline in their sales revenues 
(Sharma, et al. 2011). Based on the empirical evidence the study therefore proposes that: 
Proposition 4: The profitability of born global bio-enterprises is very much dependent on how 
they carefully manage, organise, and control their outward and inward-oriented activities irrespective 
of the commotion in the international markets. Their impetus to use entrepreneurial instincts 
cushions and propels their businesses to survive even in harsh conditions. 
Figure 2 on p.22 gives a graphical illustration of overseas sales against total turnover for 
each of the five companies. The financial results reported below demonstrate a healthy 
overseas sales performance suggesting that the bio-enterprises have greatly enhanced their 
marketing and commercialisation by using entrepreneurial marketing management strategies 
and tactics. Interestingly, the time taken to achieve these high percentages of total revenues 
in overseas markets has been short for all the bio-enterprises. This suggests that the time to 
market was significantly reduced through the use of international network channels.  
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Clearly, the realised value of bio-enterprises came from their deliberate and proactive 
efforts in biotechnology.  
Fig. 2: Overseas sales vs. total turnover in the third year of the trading period ending June 
2013 
 
The international collaborations and commercial arrangements between the UK bio-
enterprises and their complementary partners resulted in multi-dimensional skills transfer, 
with all partners gaining new insights into the expertise and processes of the other partner. 
Judging by the current revenue trends on figure 2 above, it is conceivable that in their sixth 
year of trading all the studied bio-enterprises would be generating more than 50% of their 
total sales revenue from international markets. This finding is important for technology-
based organisations in the sense that it enables them to realise that choosing a partner with 
‘strategic fit’ places them in a better position to access global markets and hedge against 
R&D risks, particularly in turbulent times.  
5.5 Perceived stakeholder benefits  
In view of the aforementioned throughput of born global enterprises, their clientele also 
benefited by accessing new drug discovery services, and technologically advanced drug 
testing processes. The pursuit for international commerce by the UK bio-enterprises 
created an economy of practice built around their inventions, creating value for all the 
partners involved, while also generating sales and enhancing overall performance. The skills-
transfer has meant that all personnel involved were fully equipped as a result of their 
involvement in co-operative networks and therefore better-placed to deal with international 
marketing management challenges.     
6. Discussion  
Entrepreneurial companies, such as those studied in this research, use their own initiatives 
for example; they engage in collaborative programmes; exploit resources embedded in local 
and international science laboratories and they localise their drug discovery services through 
marketing mix standardisation, with the sole purpose of adding value to their brand.  
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The companies combine this with international marketing management strategies that 
involve trade agreements, piggybacking, licensing, networking, partnerships and open science 
libraries to boost their propositions. In the marketing management literature (see Piercy, 
2002; Levitt, 1960), intangible assets such as brand, core competencies, skills and 
organisational processes (distribution systems for example) are seen as essential 
components that can be used to build marketing strategies. The rate at which the 
internationalised biotechnology industry evolves pushes bio-enterprises to adopt 
international marketing management methods that enhance their internal processes, while 
adding value to their clientele. Technology-based companies face significant financial 
challenges such as marketing and R&D costs involved in developing advanced technology and 
this is even made harder in saturated markets. Statistically, the East Midlands biotechnology 
sector has a high concentration of biotechnology companies (Smith and Ehret, 2013) and 
this requires born global bio-enterprises, operating in such an environment to structure 
their businesses in a way that permits them to leapfrog into the international arena more 
rapidly. Additionally, there are a number of factors that may push for this – it may be that 
there are less market pressures in niche markets due to low levels of protectionism giving 
born global bio-enterprises the impetus to exploit such market structures. An in-depth 
examination of the bio-enterprises examined in this study produced sufficient evidence 
indicating they are nimble, proactive and yet extremely well-managed and organised. They 
utilised existing and newly developed systems of co-ordination and co-operation (networks) 
within their vicinity and in multiple countries to guarantee their success. More importantly, 
this study revealed that in the biotechnology industry effective marketing and 
commercialisation of services is underpinned by marketing management strategies that 
consider both internal and external marketing forces. Based on this, it is plausible to suggest 
that designing effective marketing management programmes is very much dependent upon 
how well an organisation establishes productive connections with the main agents in their 
networks. 
7. Conclusion research implications 
The study makes a contribution to entrepreneurial and international marketing research. It 
clearly maps out the marketing and commercialisation methods adopted in the 
biotechnology sector. It also offers a fresh perspective on, and an alternative way to think 
about, marketing management strategies utilised by born global bio-enterprises which are 
valuable in the technology-based sector. In the study a frame of reference was proposed 
following an iterative process of literature review and empirical data. The newly developed 
conceptual framework is a powerful management instrument which can be employed in high 
or low tech industries to explain the marketing management processes of businesses. An 
interesting finding of this study is that; regardless of the size of a born global bio-enterprise 
forging productive networks in multiple countries alleviates risks associated with smallness 
or newness. Forging productive networks is made possible by the opening up of 
international markets as a result of trade agreements. Crucially, the exploration and 
exploitation of close-knit communities of co-operation, as conduits for accessing essential 
strategic resource embedded in them, is prevalent in biotechnology markets.  
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As such, the study infers that marketing management strategies that consider the internal 
and external environment are a pre-requisite in such technology-based industries. Results 
from case by case and cross case analysis disclose that bio-enterprises develop strategic 
partnerships with a view to facilitate co-promotion, distribution and to share R&D risks. 
This could be important knowledge for technology-based companies which may still be 
operating as lone rangers unaware of the marketing and commercial benefits of networking 
in today’s inter-connected markets.  
Furthermore, we suggest that the results of this study could be useful for policy makers (e.g. 
in the EU and for the UK government) who have a duty to support the international 
business environment by engineering multilateral trade agreements, to facilitate the 
movement and the exchange of resources. Furthermore, the study demonstrates that the 
founders of born global bio-enterprises surround themselves with an experienced top 
management team. The founders use these key members to perform essential management 
functions such as selecting business partners with a ‘strategic fit’, particularly those partners 
that have complementary marketing, commercialisation and distribution systems. This is an 
important finding which provides managers in the current technology markets with practical 
knowledge that can be invaluable in managing their businesses. The study helps business 
managers to be informed about the considered role of standardised marketing in terms of 
guaranteeing success in internationalised technology markets. As much as the deemed 
research approach is considered to be plausible the researchers are aware of its inherent 
limitations.  
The research sample used for this study predominantly consists of five bio-enterprises 
located in the East Midlands, which limits the extent to which the model/results can be 
generalised. Therefore, we suggest future studies that test the applicability of the proposed 
theoretical framework using a larger sample from different setting, so as to identify the 
propositions that hold and/or modify the ones that are superficial.       
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